Dr. O'Donnell on Transplant Considerations in Multiple Myeloma

Betsy O'Donnell, MD, discusses transplant considerations in patients with multiple myeloma.

Betsy O'Donnell, MD, medical oncologist in the Multiple Myeloma Disease Center and director of Lifestyle Medicine at the Massachusetts General Hospital, discusses transplant considerations in patients with multiple myeloma.

Historically, if a clinical trial is being run, the definition of a transplant-eligible versus -ineligible patient was based on age, usually, the age of 65 years, says O’Donnell. However, it is known that this is not how it plays out in the real world, and patients up to the age of 75 years can undergo transplant safely and receive benefit from the procedure. As such, a gray zone that exists [with regard to age]. In that area, other factors are often considered, such as ability to perform instrumental activities of daily living and comorbidities; these factors will help determine how fit or unfit a patient is and whether or not they would be able to tolerate high-dose chemotherapy with stem cell therapy versus just doing a longer induction phase, concludes O’Donnell.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD